Mark D Okusa

US Patent:

6531457, Mar 11, 2003

Filed:

Apr 5, 2001

Appl. No.:

09/827083

Inventors:

Joel M. Linden - Charlottesville VA
Gail W. Sullivan - Charlottesville VA
Ian J. Sarembock - Charlottesville VA
Timothy MacDonald - Charlottesville VA
Mark Okusa - Charlottesville VA
Irving L. Kron - Charlottesville VA
W. Michael Scheld - Earlysville VA

Assignee:

University of Virginia - Charlottesville PA
University of Virginia Patent Foundation - Charlottesville VA

International Classification:

A61K 3170

US Classification:

514 46

Abstract:

Compounds and methods are provided to treat inflammatory conditions with certain A adenosine receptor antagonists.

US Patent:

7169818, Jan 30, 2007

Filed:

Oct 3, 2001

Appl. No.:

10/398305

Inventors:

Kevin R. Lynch - Charlottesville VA, US
Timothy L. Macdonald - Charlottesville VA, US
Christopher E. Heise - New York NY, US
Webster L. Santos - Cambridge MA, US
Mark D. Okusa - Charlottesville VA, US

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

A01N 33/08

US Classification:

514667, 554 66, 554 40, 554 41, 564353, 564503

Abstract:

The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i. e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom.

US Patent:

7226913, Jun 5, 2007

Filed:

Mar 3, 2003

Appl. No.:

10/379154

Inventors:

Joel M. Linden - Charlottesville VA, US
Gail W. Sullivan - Charlottesville VA, US
Ian J. Sarembock - Charlottesville VA, US
Timothy MacDonald - Charlottesville VA, US
Mark Okusa - Charlottesville VA, US
Irving L. Kron - Charlottesville VA, US
W. Michael Scheld - Earlysville VA, US

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

A61K 31/70

US Classification:

514 46

Abstract:

The present invention provides compositions for oral administration of compounds having Aadenosine receptor agonist activity. These compositions are useful for treatment of inflammatory conditions.

US Patent:

7396825, Jul 8, 2008

Filed:

May 3, 2005

Appl. No.:

11/121169

Inventors:

Mark D. Okusa - Charlottesville VA, US
Joel M. Linden - Charlottesville VA, US
Timothy L. Macdonald - Charlottesville VA, US
Alaa S. Awad - Charlottesville VA, US

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

A01N 43/04
A61K 31/70
C07H 19/00
C07H 19/22

US Classification:

514 45, 514 43, 514 48

Abstract:

The present invention provides a therapeutic method for treating diabetic kidney disease, e. g. , diabetic nephropathy that includes the administration of an effective amount of an Aadenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor.

US Patent:

20070265440, Nov 15, 2007

Filed:

Apr 24, 2007

Appl. No.:

11/739680

Inventors:

Joel Linden - Charlottesville VA, US
Gail Sullivan - Charlottesville VA, US
Ian Sarembock - Charlottesville VA, US
Timothy MacDonald - Charlottesville VA, US
Mark Okusa - Charlottesville VA, US
Irving Kron - Charlottesville VA, US
W. Scheld - Earlysville VA, US

International Classification:

C07H 19/06

US Classification:

536027300

Abstract:

Compositions for oral administration of compounds having Aadenosine receptor antagonist activity are provided. These compositions are useful for treatment of inflammatory conditions.

US Patent:

62322974, May 15, 2001

Filed:

Jun 15, 1999

Appl. No.:

9/333387

Inventors:

Joel M. Linden - Charlottesville VA
Gail W. Sullivan - Charlottesville VA
Ian J. Sarembock - Charlottesville VA
Timothy MacDonald - Charlottesville VA
Mark Okusa - Charlottesville VA

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

A61K 3170
C07H 1916
C07H 19167
C07H 19173

US Classification:

514 46

Abstract:

Compounds and methods are provided to treat inflammatory conditions with certain A. sub. 2A adenosine receptor antagonists.

US Patent:

20180016317, Jan 18, 2018

Filed:

Aug 18, 2017

Appl. No.:

15/680320

Inventors:

- Charlottesville VA, US
Mark D. Okusa - Charlottesville VA, US

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

C07K 14/55
C07K 14/54
A61K 38/00

Abstract:

The present application discloses a novel fusion peptide of IL-2 and IL-33 and its use. It comprises a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment or homolog thereof, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment or homolog thereof. The two portions can be linked by a linker sequence. The application discloses that combination therapies using IL-2 and IL-33 or a therapy using the IL233 fusion protein are effective in preventing or treating diseases and disorders such as autoimmune diseases and disorders, inflammation, etc. Depending on the subject's disease or disorder, the compositions of the invention are useful for preventing certain symptoms, treating the disease, and alleviating at least some of the symptoms.

US Patent:

20160304574, Oct 20, 2016

Filed:

Sep 22, 2014

Appl. No.:

15/026927

Inventors:

Rahul SHARMA - Charlottesville VA, US
Mark D. OKUSA - Charlottesville VA, US
- Charlottesville VA, US

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

C07K 14/55
C07K 14/54

Abstract:

The present application discloses a novel fusion peptide of IL-2 and IL-33 and its use. It comprises a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment or homolog thereof, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment or homolog thereof. The two portions can be linked by a linker sequence. The application discloses that combination therapies using IL-2 and IL-33 or a therapy using the IL233 fusion protein are effective in preventing or treating diseases and disorders such as autoimmune diseases and disorders, inflammation, etc. Depending on the subject's disease or disorder, the compositions of the invention are useful for preventing certain symptoms, treating the disease, and alleviating at least some of the symptoms.